Standard anti-tumor treatment
Phase 3Small molecule
Standard anti-tumor treatment is one of 27 small molecule programs targeting Lung Cancer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
686 competitors in Lung Cancer
#DrugCompanyPhaseTrials
1Tecentriq
RochePreclinical
Libtayo
RegeneronPreclinical
Vizimpro
PfizerPreclinical
Standard anti-tumor treatment
QQinghai Red Cross Hospital
Phase 3
Talzenna
PfizerPreclinical
Folvite
Eli LillyPreclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Paclitaxel and Carboplatin
Bristol-Myers SquibbPreclinical
Rilotumumab
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- QQinghai Red Cross Hospital